De-escalated neoadjuvant nab-paclitaxel combined with pyrotinib and trastuzumab in intrinsic HER2-enriched breast cancer (NJMU-BC01): a multicenter, single-arm, phase 2 trial
Authors
Xiaoan Liu (ORCID: https://orcid.org/0000-0001-5716-0740)
Min Zha (ORCID: https://orcid.org/0000-0002-0499-9224)
Tiansong Xia
Shui Wang (ORCID: https://orcid.org/0000-0001-8878-9162)
De-escalated neoadjuvant nab-paclitaxel combined with pyrotinib and trastuzumab in intrinsic HER2-enriched breast cancer (NJMU-BC01): a multicenter, single-arm, phase 2 trial
Xiaoan Liu, Min Zha, Tiansong Xia, Shui Wang et al.
Citations
1 citations
Journal
EClinicalMedicine
Topics
HER2/EGFR in Cancer Research
Field-Weighted Citation Impact (FWCI)
1.05
article
De-escalated neoadjuvant nab-paclitaxel combined with pyrotinib and trastuzumab in intrinsic HER2-enriched breast cancer (NJMU-BC01): a multicenter, single-arm, phase 2 trial
Xiaoan Liu, Min Zha, Tiansong Xia, Shui Wang, Wenbin Zhou, Hui Xie, Qiang Ding, Cong Wang, Yi Ren, Xiaoming Zha, Zhao Liu, Lin Chen, Wei Li, Tao Jing, Yi Zhao, Hua Pan, Yue Sun, Hong Pan, Mingduo Liu
article en
1 citations
Abstract
No abstract available for this paper.
Publication Tag
EClinicalMedicineVol. 86
Institutions
Xuzhou Medical College (CN), Huaian First People’s Hospital (CN), Deyang Stomatological Hospital (CN), Second Affiliated Hospital of Nanjing Medical University (CN), Liuyang City Maternal and Child Health Hospital (CN), Nanjing Medical University (CN)